Chalcogen Bonded Directly To Ring Carbon Of The Five-membered Hetero Ring Patents (Class 514/418)
-
Publication number: 20120184592Abstract: Compounds and methods for treating cancer or inducing apoptosis in proliferating cells. The compounds are shown in formula I: wherein X is selected from hydroxyl, thiol, and amino; Y is selected from carboxyl and sulfonyl; R1, R2, R3, and R4 are selected from hydrogen, lower alkyl, and combinations thereof; R5, R6, and R7 are selected from hydrogen, halo, nitro, amino, methoxy, and combinations thereof; and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 26, 2012Publication date: July 19, 2012Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Ching-Shih Chen, Jing-Ru Weng
-
Publication number: 20120178764Abstract: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.Type: ApplicationFiled: January 5, 2012Publication date: July 12, 2012Inventors: Roger Bonnert, Rukhsana (née RASUL, Rukhsana) Mohammed, Mark Robert Dickinson
-
Patent number: 8217051Abstract: There are provided compounds of the formula or a pharmaceutically acceptable salt or ester thereof wherein X, Y, R1, R2 are as herein described. The compounds have utility as antiproliferative agents, especially, as anticancer agents.Type: GrantFiled: January 7, 2010Date of Patent: July 10, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Jing Zhang, Zhuming Zhang
-
Publication number: 20120149751Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).Type: ApplicationFiled: February 22, 2012Publication date: June 14, 2012Applicant: Siga Technologies, Inc.Inventors: Dennis E. Hruby, Tove C. Bolken, Sean Amberg, Dongcheng Dai
-
Patent number: 8198313Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: January 10, 2011Date of Patent: June 12, 2012Assignee: H. Lundbeck A/SInventors: Michael Konkel, John M. Werzel, Jamie Talisman
-
Publication number: 20120142646Abstract: The present invention provides compounds of formula (I) wherein k, Ar, R2, R3, R4, R5, R4?, R5?, R6, R7, A, D, m and E are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: December 19, 2007Publication date: June 7, 2012Inventors: Lilian Alcaraz, Roger Victor Bonnert, Stephen Connolly, Anthony Ronald Cook, Adrian Fisher, Alexander Humphries, Piotr Raubo
-
Publication number: 20120130144Abstract: In one aspect, the present invention provides a method of treating lung cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one growth factor inhibitor. In another aspect, the present invention provides a method of treating non-small cell lung cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one growth factor inhibitor.Type: ApplicationFiled: February 4, 2010Publication date: May 24, 2012Applicant: BiPar Sciences, Inc.Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
-
Publication number: 20120128665Abstract: The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.Type: ApplicationFiled: November 18, 2011Publication date: May 24, 2012Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Ronald K. Blackman, Vojo Vukovic
-
Publication number: 20120122910Abstract: Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells, comprising G2/M stage arrest, in a patient by administering a compound of formula (I), (II), (III), or (IV) are also disclosed. Further disclosed herein are methods of inducing apoptosis in cancer cells in a patient by administering a compound of formula (I), (II), (III), or (IV).Type: ApplicationFiled: January 19, 2010Publication date: May 17, 2012Applicant: The Trustees Of The University Of PennsylvaniaInventors: Alan Berezov, Qiang Wang, Ramachandran Murali, Mark I. Greene
-
Publication number: 20120122878Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.Type: ApplicationFiled: June 30, 2008Publication date: May 17, 2012Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
-
Publication number: 20120115842Abstract: The invention relates to novel oxindole derivatives of general formula (I), wherein substituents A, B, X and Y are defined as in claim 1, medicaments containing said derivatives, and the use thereof in the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.Type: ApplicationFiled: December 30, 2005Publication date: May 10, 2012Inventors: Wilfried Lubisch, Thorsten Oost, Liliane Unger, Wilfried Hornberger, Herve Geneste
-
Publication number: 20120107304Abstract: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor.Type: ApplicationFiled: April 19, 2011Publication date: May 3, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Flavio Solca, Ulrich Guertler, Ulrike Tontsch-Grunt
-
Publication number: 20120101067Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.Type: ApplicationFiled: April 15, 2010Publication date: April 26, 2012Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
-
Publication number: 20120094998Abstract: The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water soluble, non peptidic oligomer.Type: ApplicationFiled: April 19, 2010Publication date: April 19, 2012Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang
-
Publication number: 20120077759Abstract: Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.Type: ApplicationFiled: September 15, 2011Publication date: March 29, 2012Applicant: President and Fellows of Harvard CollegeInventors: José A. Halperin, Amarnath Natarajan, Bertal Huseyin Aktas, Yun-Hua Fan, Han Chen
-
Patent number: 8138220Abstract: [2-(6-fluoro-1H-indol-3-ylsulfanyl)benzyl]methyl amine and pharmaceutically acceptable salts thereof, provided it is not the free base in a non-crystalline form are provided for the treatment of affective disorders.Type: GrantFiled: September 27, 2007Date of Patent: March 20, 2012Assignee: H. Lundbeck A/SInventors: Jan Kehler, Karsten Juhl
-
Publication number: 20120052113Abstract: The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4E indolone and a physiologically active compound.Type: ApplicationFiled: May 7, 2010Publication date: March 1, 2012Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Naoyuki Uchida, Yuka Takagi, Yasunori Takada
-
Patent number: 8124647Abstract: This invention provides non-steroidal compounds with affinity for the androgen receptor and utility for androgen-receptor related treatments, having a structure according to the formula or a salt or hydrate form thereof.Type: GrantFiled: September 3, 2010Date of Patent: February 28, 2012Assignee: N.V. OrganonInventors: Pedro Harold Han Hermkens, Herman Thijs Stock, Jaap Van Der Louw, Neeltje Miranda Teerhuis, Johannes Petrus Maria Lommerse
-
Publication number: 20120034270Abstract: The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.Type: ApplicationFiled: October 16, 2009Publication date: February 9, 2012Applicant: Akaal Pharma Pty LtdInventors: Damian W. Grobelny, Gurmit S. Gill
-
Publication number: 20120004202Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.Type: ApplicationFiled: March 31, 2011Publication date: January 5, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: John Edward PARK, Nveed CHAUDHARY, Gerald Juergen ROTH, Armin HECKEL, Thorsten LEHMANN-LINTZ, Joerg KLEY
-
Publication number: 20120004165Abstract: Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments The invention relates to heterocyclically substituted methoxyphenyl derivatives with an oxo group, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R10, X, n, B1, B2, B3 and B4 are each defined as specified, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.Type: ApplicationFiled: June 7, 2011Publication date: January 5, 2012Applicant: SANOFIInventors: Stefanie KEIL, Elisabeth DEFOSSA, Viktoria DIETRICH, Siegfried STENGELIN, Andreas HERLING, Guido HASCHKE, Thomas KLABUNDE
-
Patent number: 8088816Abstract: Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl) -3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.Type: GrantFiled: June 9, 2010Date of Patent: January 3, 2012Assignee: President and Fellows of Harvard CollegeInventors: José A. Halperin, Amarnath Natarajan, Huseyin Aktas, Yun-Hua Fan, Han Chen
-
Publication number: 20110319387Abstract: The invention relates to a compound of the following formula (I), or to a pharmaceutically acceptable salt thereof or to a stereoisomer or mixture of stereoisomers at any proportions, where: X1 is a CH2 or C?O group; X2 is a linear saturated or unsaturated carbohydrate chain with 8 to 24 carbon atoms; R1 is a hydrogen atom or an OH or (C1-C6)alkoxy group such as methoxy; and R2 is a CH3 or CH2OR3 group, with R3 being a hydrogen atom or a (C1-C6)alkyl, CO—(C1-C6)alkyl or NH—(C1-C6)alkyl group. The invention also relates to the use of said compound as a drug, in particular for treating neurodegenerative diseases, and to a method for preparing same.Type: ApplicationFiled: March 2, 2010Publication date: December 29, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Fanny Schmidt, Bruno Figadere, Rita Raisman-Vozari, Pierre Champy
-
Patent number: 8084487Abstract: The present invention relates to a process for the production of carbamic acid (2-chloroethyl)(3-oxocyclohexyl)-alkyl ester enantiomers and of 1-carbalkoxy-4-ketoperhydroindole enantiomers.Type: GrantFiled: August 10, 2009Date of Patent: December 27, 2011Assignee: Novartis AGInventors: Ernst Kuesters, Murat Acemoglu, Philipp Lustenberger, Gottfried Sedelmeier, Beat Schmitz, Gerhard Penn
-
Publication number: 20110311613Abstract: Described herein, are topical formulations for treating a dermatological disease, disorder, or condition.Type: ApplicationFiled: December 21, 2009Publication date: December 22, 2011Applicant: AMIRA PHARMACEUTICAL, INC.Inventors: John Howard Hutchinson, Jillian F. Evans, Kevin Murray Schaab
-
Patent number: 8080577Abstract: The present invention relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane and diindolylmethane-related indoles. The present invention also relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane in combination with an EGFR antagonist. The methods provide non-invasive treatments for leiomyomas.Type: GrantFiled: May 6, 2005Date of Patent: December 20, 2011Assignee: Bioresponse, L.L.C.Inventor: Michael A. Zeligs
-
Publication number: 20110287097Abstract: Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form.Type: ApplicationFiled: August 14, 2008Publication date: November 24, 2011Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITEDInventors: Hemanth Prakash Joshi, Narayanan Badri Vishwanathan
-
Publication number: 20110286995Abstract: Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.Type: ApplicationFiled: June 13, 2011Publication date: November 24, 2011Inventors: CHAITAN KHOSLA, KIHANG CHOI
-
Patent number: 8058269Abstract: There is provided compounds of the formula wherein R6, V, W, X, Y, Q and n are as described. The compounds exhibit activity as anticancer agents.Type: GrantFiled: September 17, 2007Date of Patent: November 15, 2011Assignee: Hoffman-La Roche Inc.Inventors: Li Chen, Song Yang, Jing Zhang, Zhuming Zhang
-
Publication number: 20110275645Abstract: The invention provides compounds that inhibit protein kinases, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and/or prodrugs, pharmaceutical compositions including the compounds and/or prodrugs and methods of using the compounds and/or prodrugs in a variety of contexts, including, for example, in the treatment and/or prevention of various diseases that are responsive to protein kinase inhibition and/or that are mediated, at least in part, by inappropriate kinase activity.Type: ApplicationFiled: May 5, 2010Publication date: November 10, 2011Inventors: Renee Desai, Ketan Desai
-
Publication number: 20110275689Abstract: The present invention relates to novel intermediates and further to the use of said intermediates in processes for the preparation of indolinone derivatives, in particular 3-pyrrole substituted 2-indolinones having amide moieties on the pyrrole ring. Such compounds are useful in die treatment of abnormal cell growth, such as cancer, in mammals.Type: ApplicationFiled: July 1, 2009Publication date: November 10, 2011Applicant: GENERICS [UK] LIMITEDInventors: Abhay Gaitonde, Bharati Choudhari, Prakash Bansode, Sunanda Phadtare
-
Publication number: 20110269812Abstract: The present invention relates generally to organic chemistry, biochemistry, pharmacology and medicine. More particularly, it relates to 3-benzylidene-indolin-2-one derivatives and their physiologically acceptable salts and prodrugs which modulate the activity of protein kinases (“PKs”), especially protein tyrosine kinase, and, therefore, are expected to exhibit a salutary effect against disorders related to abnormal PK activity. The present invention is further directed to methods of using of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of protein kinase-mediated diseases and disorders, such as cancer.Type: ApplicationFiled: October 14, 2009Publication date: November 3, 2011Applicants: Agency for Science, Technology and Research, National University of SingaporeInventors: Mei Lin Go, Han Kiat Ho, Wei Zhang
-
Publication number: 20110269807Abstract: The invention relates to compounds, compositions, drug delivery systems, and methods for treating age-related macular degeneration (AMD) and ocular ischemic disease in an individual in need.Type: ApplicationFiled: April 29, 2011Publication date: November 3, 2011Applicant: ALLERGAN, INC.Inventor: Peter C. Baciu
-
Publication number: 20110262537Abstract: There is provided an extended release tablet in tablet dosage form of ropinirole or salts thereof comprising a) an inner tablet of ropinirole or salts thereof optionally with other pharmaceutically acceptable excipients and b) an outer tablet of other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising a core of ropinirole or salt thereof and outer mantle coating comprising one or more pharmaceutically acceptable excipients. The invention also relates to processes of preparing such compositions.Type: ApplicationFiled: September 29, 2009Publication date: October 27, 2011Inventors: Premchand Nakhat, Venkatesh Joshi, Prashant Mandaogade, Girish Kumar Jain
-
Publication number: 20110263565Abstract: The present invention encompasses compounds of general formula (1), wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.Type: ApplicationFiled: July 28, 2009Publication date: October 27, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias Treu, Thomas Karner, Ulrich Reiser
-
Publication number: 20110263614Abstract: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.Type: ApplicationFiled: March 14, 2011Publication date: October 27, 2011Inventors: Roger Bonnert, Rukhsana Mohammed, Mark Robert Dickinson
-
Publication number: 20110263540Abstract: Small-molecule inhibitors of a protein synthesis inhibiting toxin, e.g., ricin, abrin, Shiga, and Shiga-like toxins, as well as methods of using the inhibitors are provided. Further provided are methods of identifying small-molecule inhibitors of a protein synthesis inhibiting toxin.Type: ApplicationFiled: July 24, 2009Publication date: October 27, 2011Inventors: Yuan-Ping Pang, Nilgun Ereken Tumer, Charles B. Millard
-
Publication number: 20110263585Abstract: The present invention relates to polypeptides, preferably from Drosophila melanogaster (DmShaI) as target for insecticides.Type: ApplicationFiled: November 5, 2009Publication date: October 27, 2011Applicant: BASF SEInventors: Paul Bernasconi, John Dorsch, Lynn Stam, Scott Zitko, Nancy B. Rankl, Mike Griswold, Franz-Josef Braun, Gang Lu, Robert D. Kirkton, Barbara Wedel, Joachim Dickhaut, Angela Hofhine, Jennifer Zink, Fae Malone, Daniel Houtz, Steffen Gross, Ramani Kandasamy, Damian London, Thomas M. Gurganus
-
Publication number: 20110263671Abstract: Pharmaceutically acceptable salts of sunitinib, processes of making sunitinib salts, as well as related pharmaceuticals and methods of treating are described.Type: ApplicationFiled: October 28, 2009Publication date: October 27, 2011Inventor: Lovro Selic
-
Patent number: 8044090Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.Type: GrantFiled: July 16, 2009Date of Patent: October 25, 2011Assignee: Eli LillyInventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
-
Patent number: 8039484Abstract: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.Type: GrantFiled: October 26, 2007Date of Patent: October 18, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Min Ge, Songnian Lin, Shawn P. Walsh, Lihu Yang, Changyou Zhou
-
Publication number: 20110251200Abstract: The invention provides to a family of aryl guanidine-based F1F0-ATPase inhibitors, e.g., mitochondrial F1F0-ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders.Type: ApplicationFiled: September 11, 2009Publication date: October 13, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Gary D. Glick, Peter Toogood, Gina Ney
-
Patent number: 8034806Abstract: In one aspect, the invention relates to bicyclic MGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: October 31, 2008Date of Patent: October 11, 2011Assignee: Vanderbilt UniversityInventors: P. Jeffrey Conn, Craig W. Lindsley, Charles David Weaver, Alice L. Rodriguez, Colleen M. Niswender, Carrie K. Jones, Richard Williams
-
Publication number: 20110243957Abstract: The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability.Type: ApplicationFiled: September 24, 2009Publication date: October 6, 2011Applicants: University of South Florida, United States Department of Veterans AffairsInventors: Valentina Echeverria Moran, Gary W. Arendash
-
Publication number: 20110245261Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for promoting a substantial reduction of lactation, mammary involution, and for treating and/or intra-mammary diseases or infections of ruminants.Type: ApplicationFiled: April 7, 2011Publication date: October 6, 2011Applicant: CEVA SANTE ANIMALE SAInventors: Anouck LAGARDE, Stephane FLOCH, Thierry BERTAIM
-
Publication number: 20110243917Abstract: The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food.Type: ApplicationFiled: August 5, 2010Publication date: October 6, 2011Inventors: Eunji Cheong, Hee-Sup Shin, Yihong Zheng, Kyoobin Lee, Jungryun Lee, Seongwook Kim, Maryam Sanati, Sukyung Lee, Yeon-Soo Kim
-
Publication number: 20110237563Abstract: The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk. Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk.Type: ApplicationFiled: March 23, 2010Publication date: September 29, 2011Inventor: Dominique Costantini
-
Publication number: 20110230513Abstract: Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100.Type: ApplicationFiled: June 7, 2009Publication date: September 22, 2011Applicant: PHARMA TWO B LTD.Inventors: Itschak Lamensdorf, Yoram Sela
-
Publication number: 20110201629Abstract: There are described cyclohexyl amide derivatives of Formula I, which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.Type: ApplicationFiled: January 31, 2011Publication date: August 18, 2011Inventors: Benjamin Atkinson, David Beattie, Andrew James Culshaw, James Dale, Nicholas James Devereux, Jeffrey McKenna
-
Publication number: 20110195117Abstract: A novel oral controlled release pharmaceutical composition comprising a therapeutically effective amount of active substance, ropinirole or a pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) or hydrate(s) thereof, one or more controlled release agent(s), optionally one or more pharmaceutically acceptable excipient(s) and an extended release coating, wherein the said composition provides controlled release of the active agent with reduced initial burst release.Type: ApplicationFiled: September 1, 2009Publication date: August 11, 2011Applicant: Lupin LimitedInventors: Arvind Mohan Upadhyay, Girish Bang, Nikhil Malewar, Makrand Avachat